TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Focal Ablation of the Prostate With NanoTherm® Therapy System for Intermediate-Risk Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 40 to 85~* Male~* Prostate adenocarcinoma on biopsy~* Clinical stage T1c/T2a/T2b, N0, M0/Mx with no lesion larger than 2cc in volume~* The following biopsy findings (biopsy must have MRI visualization and be within 6 months of planned NanoTherm® treatment):~  * A positive biopsy for prostate cancer from the MRI-visualized lesion, at least one of which must be Gleason 3+4 (grade group 2)~* Lesion must be visualized by Multiparametric Magnetic Resonance Imaging (MP-MRI) on a scan that is less than 6 months old~* Patient expresses a preference for active surveillance, rather than surgery or radiation, to manage prostate cancer~* Based on the evaluation of the study investigator, appropriate for instillation of NanoTherm® under anesthesia based on location and size of the clinical target volume (CTV)~Exclusion Criteria:~* Previous treatment for cancer with radiation, androgen deprivation (including LHRH-agonists or antagonists or antiandrogens), or surgery for prostate cancer~* Active urinary tract infection~* Metallic implants below the neck~* Gleason 3+4 or higher cancer on prostate biopsy outside of the planned CTV~* Gleason 4+3 or higher on any prostate biopsy~* Hematological abnormality indicating increased risk of bleeding or clotting, for example low platelet count or anemia~* Participation concurrently in another clinical trial for prostate disease or in the last 30 days~* Known hypersensitivity to Axumin®

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Ablation Arm (Type: EXPERIMENTAL): Subjects in this arm of the study will have focal ablation of the prostate cancer lesion with the NanoTherm technology. This ablation will be followed-up transperineal prostate biopsy at 4 months after treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed transitional cell carcinoma of the bladder~  * Locally advanced or metastatic disease~* Unidimensionally measurable disease by physical exam or imaging study~  * The following are not considered measurable disease:~    * Bone only disease~   * Pleural or peritoneal effusions~   * CNS lesions~   * Irradiated lesions unless disease progression was documented after radiotherapy~* Not amenable to surgery~PATIENT CHARACTERISTICS:~Age~* Over 18~Performance status~* ECOG 0-2~Life expectancy~* Not specified~Hematopoietic~* Granulocyte count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~Hepatic~* Bilirubin ≤ 2.0 mg/dL~Renal~* Creatinine ≤ 2.0 mg/dL~Gastrointestinal~* No active inflammatory bowel disease~* No significant bowel obstruction~* No chronic diarrhea~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No other active malignancy except nonmelanoma skin cancer~* No mental incapacitation or psychiatric illness that would preclude giving informed consent~* No other severe disease that would preclude study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No concurrent prophylactic filgrastim (G-CSF) or sargramostim (GM-CSF)~Chemotherapy~* No more than 1 prior platinum-based chemotherapy regimen~* At least 4 weeks since prior chemotherapy~* No prior irinotecan or gemcitabine~* No other concurrent chemotherapy~Endocrine therapy~* No concurrent hormones except steroids for adrenal failure, hormones for non-disease-related conditions (e.g., insulin for diabetes), and intermittent dexamethasone as an antiemetic~Radiotherapy~* See Disease Characteristics~* At least 4 weeks since prior radiotherapy~* No concurrent palliative radiotherapy~Surgery~* Not specified~Other~* No concurrent participation in another clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Gemcitabine and Irnotecan (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Traditional Chinese Medicine on In Vitro Fertilization (IVF) Success Rates

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is able to understand and provide consent~2. Subject is female, 21-42 years of age at time of screening and has at least one l ovary~3. Subject BMI is \> 18 and \< 32~4. Subject is experiencing primary or secondary infertility~5. Subject may receive sperm from donated source~6. Subject's partner has sperm in the ejaculate~7. Subject's serum basal FSH is \< 11 IU/L~8. Subject's serum basal estradiol level is between 20-80 pg/mL~9. Subject's TSH level is \< 3.0 mv/mL~10. Subject's prolactin level is \< 24 ng/mL~11. Subject will agree to limit caffeine intake to one cup (76.5 mL/day) by the time of randomization~12. Subject agrees not to make alterations in diet and lifestyle practices other than those that their Medical Practitioner deems necessary in the best interest of the subject~13. Subject agrees not to participate in any other research opportunities for the duration of the study~Exclusion Criteria:~1. Subject is pursuing sex selection~2. Subject is undergoing treatment with an egg donor~3. Subject experienced more than 2 previous failed cycles~4. Subject is undergoing a heparin or lovenox-based protocol~5. Subject is currently taking herbal therapy (1 week wash-out)~6. Subject is currently taking co-interventions of moxibustion and cupping~7. Subject is exhibiting uterine anomalies (i.e.,bicornuate, unicornuate uterus,)~8. Subject is diagnosed with severe endometriosis defined as endometriomas \> 4cm~9. Subject is currently receiving acupuncture therapy (Subject must agree to a 30 day washout period prior to randomization)~10. Subject has history of recurrent spontaneous abortions defined as \> 3~11. Subjects with a Beck Depression Inventory (BDI-II) of 29 or higher at screening, indicative of severe depression, will be excluded from the study and referred for further psychological evaluation by our in-house licensed mental health professional.

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 42 Years
- Healthy Volunteers: t

Study Arms:
- IVF-No Acupuncture (Type: NO_INTERVENTION): IVF with no Traditional Chinese Medicine: Acupuncture
- IVF-Acupuncture (Type: ACTIVE_COMPARATOR): IVF with Traditional Chinese Medicine: Acupuncture

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Budesonide/Formoterol Turbuhaler® Versus Terbutaline Nebulization as Reliever Therapy in Children With Moderate Asthma Exacerbation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children 8-17 years~* Children consulting to the ER with moderate asthma exacerbation (defined by the Pulmonary Score \> 3 and ≤7)~* Score for the inhalation technique = 3~* French social security affiliation~Exclusion Criteria:~* Pneumonia~* Pulmonary and/or cardiac congenital malformations~* Chronic pulmonary disease other than asthma (bronchopulmonary dysplasia, cystic fibrosis, or post infectious bronchiolitis obliterans)~* Foreign body aspiration~* Neurological alteration~* Severe asthma exacerbation defined by Pulmonary Score \> 7~* Cardiopulmonary failure imminent or mechanical ventilation indication~* Thyrotoxicosis, pheochromocytoma, type 2 diabetes, untreated hypokalemia, obstructive cardiomyopathy, idiopathic subvalvular aortic stenosis, severe hypertension, aneurysm or other serious cardiovascular disorders such as ischemic heart disease, tachyarrhythmias or severe heart failure.~* Pregnancy~* Breastfeeding woman~* Ongoing participation in RIPH1 Intervention Research~* History of intolerance to terbutaline~* Hypersensitivity to the active ingredient or any excipients of terbutaline~* Hypersensitivity (allergy) to budesonide, formoterol or any component of the product (lactose may contain milk proteins in small quantities)~* Patient with an ongoing treatment of itraconazole, ritonavir or other potent CYP3A4 inhibitor, quinidine, disopyramide, procainamide, phenothiazines, antihistamines (terfenadine), monoamine oxidase inhibitors (MAOIs), beta-blockers (including eyedrops) and tricyclic antidepressants

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- budesonide/formoterol Turbuhaler® (Type: EXPERIMENTAL): After randomization, patients in the experimental arm will receive budesonide/formoterol Turbuhaler® 100/6 μg, one inhalation every 5 minutes (Maximum 12 inhalations).
- nebulisation of terbutaline (Type: ACTIVE_COMPARATOR): 0.1 mg/kg nebulized terbutaline 5 mg/2 ml of Terbutaline dilution diluted with 2 ml normal saline delivered by an air compressor nebuliser driven by oxygen at a flow rate of 8l/min. The duration of one dose will be approximately 20 minutes and a total of 3 doses will be administered. In case of an insufficient response, 3 additional doses will be administered for a maximum of 6 nebulisations.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed adenocarcinoma of the colon~  * Metastatic or recurrent disease~ * Redocumentation of tumor histology or cytology prior to protocol therapy is not required if documented tumor was confirmed prior to initial therapy~* Measurable disease~  * Lesion of ≥ 1 cm in longest diameter that can be repetitively assessed by radiographic measurement or any lesion of ≥ 2 cm in longest diameter that can be repetitively assessed by physical examination~ * Positive bone scans, osteoblastic or osteolytic bone lesions, pleural effusions, and positive bone marrow biopsies are not considered measurable or evaluable lesions~* Metastatic disease to the brain allowed if emergent radiotherapy for symptomatic CNS disease is not required~* Must have received at least one prior chemotherapy regimen (with or without radiotherapy)~  * One of the prior regimens must include irinotecan hydrochloride, fluorouracil, and leucovorin calcium or irinotecan hydrochloride and other fluoropyrimidine~ * Previous therapy with C-225 and/or bevacizumab is allowed~* .~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Granulocyte count ≥1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Creatinine ≤ 2.0 mg/dL~* Bilirubin \< 1.5 mg/dL~* SGOT ≤ 2 times upper limit of normal (ULN)~* Alkaline phosphatase \< 2.5 times ULN~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No serious medical or psychiatric illness that would render chemotherapy unsafe~* No concurrent clinically evident malignancy except inactive nonmelanoma skin cancer, low-grade low-stage bladder carcinoma followed off therapy, or lobular neoplasia of the breast~* No clinical AIDS or known positive HIV serology~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Recovered from prior therapy~* No investigational agent for at least 30 days prior to study entry~* No chemotherapy within the past 3 weeks~* No radiotherapy for palliation within the past 2 weeks prior to study entry~* No prior oxaliplatin or gemcitabine hydrochloride~* No concurrent participation in another clinical trial~* No other concurrent anticancer therapy including chemotherapy, radiotherapy, hormonal therapy, or immunotherapy~* No other concurrent investigational drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: 99mTc Sestamibi Scans In Thyroglobulin Positive Scan Negative Differentiated Thyroid Cancer (DTC) Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older;~* Diagnosed with differentiated thyroid carcinoma;~* At least one prior I-131 therapy, which may be remnant ablation, adjuvant treatment, and/or treatment of distant metastases,~* Elevated suppressed or stimulated thyroglobulin level (Tg) \> 10 ng/ml with or WITHOUT thyroglobulin antibodies ,~* All NEGATIVE standard diagnostic clinical imaging studies (SDCIS) = negative ultrasound (US), diagnostic radioiodine scan (DRS), chest-x-ray (CXR), computer tomography with or without contrast (CT), and 18F-Fluoro-deoxyglucose positron emission computer tomography scan (18F-FDG PET) within the last 12 mos.~* If extensive diagnostic clinical imaging studies (EDCIS) of 18F-sodium fluoride positron emission computer tomography scan (18F NaF PET) or 99mTc methylene diphosphonate bone scan (99mTc MDP), AND brain CT or magnetic resonance (MR) are performed, these are also negative.~Exclusion Criteria:~* \< 18 years of age;~* Pregnant or breast feeding~* Any SDCIS or EDCIS that is positive and/or suggestive of recurrent and/or distant metastases secondary to DTC. If a study is indeterminate, this will be forwarded to a committee for review and resolution.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 99mTc sestamilbi (Type: EXPERIMENTAL): 25 mCi 99mTc sestamibi intravenous injection, once. Then imaged for 45 minutes. More imaging might be required and this will be determined by a nuclear medicine physician onsite

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Two Stepped Care Models for Posttraumatic Stress Disorder (PTSD) Among Cambodian Refugees With PTSD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* PTSD;~* PCL great or equal to 44;~* Survivor of the Cambodian genocide;~* At least 7 years old at the time of the Cambodian genocide~Exclusion Criteria:~* Pregnant;~* Active suicidality;~* Mental retardation;~* Organic mental disorder;~* Bipolar disorder;~* Alcohol dependence;~* Marijuana dependence;~* Unable to give conformed consent

- Gender: ALL
- Minimum Age: 43 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Medication augmentation (Type: ACTIVE_COMPARATOR): In one arm, the patients will be given a medication augmentation for SSRI/SSRN-resistant PTSD
- CBT augmentation (Type: ACTIVE_COMPARATOR): In this arm, patients will receive CBT to treat SSRI/SSRN-resistant PTSD.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation and Treatment of Copper/Zinc Imbalance in Children With Autism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 3-8 years~* Diagnosis of autism spectrum disorder~* Serum copper/zinc ratio greater than 2.0 or as determined in phase 1 of the study~Exclusion Criteria:~* Known chromosomal disorder or neurological disorders other than autism

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 8 Years
- Healthy Volunteers: t

Study Arms:
- Oral zinc and vitamin C supplementation (Type: ACTIVE_COMPARATOR): Participant will receive oral zinc and vitamin C supplementation based on the child's weight. Blood levels of zinc, copper, liver and renal function as well as blood counts will be measured. Copper to zinc ratio will be calculated at 6 and 16 weeks
- Oral Placebo (Type: PLACEBO_COMPARATOR): Participant will receive placebo liquid with volume based on child's weight to match the amount given to participants in the experimental group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed anal cancer~  * Squamous cell disease~ * Locally advanced, non-metastatic disease~ * One of the following clinical TNM stages:~    * T2, N0, M0 (largest diameter ≥ 3 cm)~   * T3-T4, N0, M0~   * Any T, N1-N3, M0~* No undifferentiated small cell carcinoma or adenocarcinoma~* Measurable disease according to RECIST criteria~* Undergone endorectal ultrasound or MRI to evaluate the primary tumor~* Undergone thoraco-abdomino-pelvic scan to evaluate tumor extension~* Disease suitable to receive radiotherapy and chemotherapy~PATIENT CHARACTERISTICS:~* ECOG performance status 0-1~* Leukocytes ≥ 4,000/mm\^3~* ANC ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 10 g/dL~* Creatinine clearance \> 60 mL/min~* ALT and AST ≤ 5 times upper limit of normal (ULN)~* Alkaline phosphatase ≤ 2.5 times ULN~* Total bilirubin ≤ 1.5 times ULN~* Not pregnant or nursing~* Negative pregnancy test~* No history of cancer within the past 8 years except for in situ cervical cancer or previously treated basal cell carcinoma of the skin~* No contraindications to any component of study therapy~* No serious uncontrolled illness~* No symptomatic grade 1 angina pectoris or angina pectoris ≥ grade 2~* No congestive heart failure~* No peripheral sensory neuropathy~* No uncontrolled diabetes~* No HIV positivity~* No geographical, social, or psychological situations that preclude medical follow up~* Affiliated with a social security system~* No patient deprived of liberty or under trusteeship~PRIOR CONCURRENT THERAPY:~* Patients with a diverting colostomy are eligible~* No prior excision of this tumor~* No prior chemotherapy or radiotherapy for the treatment of this cancer or any other history of radiotherapy or pelvic brachytherapy~* No concurrent coumarin anticoagulants, phenytoin, sorivudine or brivudine, antacids, or allopurinol~* Not registered in another clinical trial with an experimental drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: A Stratified Sickle Event Randomized Trial (ASSERT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 16 to 65 years of age (inclusive)~* Male or female (not capable of becoming pregnant or using appropriate birth control)~* Medical history of sickle cell disease~* Have a history of at least two or more acute sickle-related painful crises requiring a visit to a medical facility within the preceding 12 months~Exclusion Criteria:~* Hemoglobin \<4 or \>11 g/dL~* On a chronic transfusion program~* Has significant active and poorly controlled (unstable) cardiovascular, neurologic, endocrine, hepatic, or renal disorders clearly unrelated to sickle cell disease

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy